The management at Meril Life Sciences knew the risks but rolled the dice anyway.

In 2013, the stent manufacturer based in Vapi, Gujarat launched its most ambitious research program yet. A new type of stent—a wafer-thin metal mesh scaffold that props open clogged arteries—had come into the market and was being hailed globally as a breakthrough in treating coronary heart disease. The USP of this stent, called “Absorb” and manufactured by Abbott Laboratories in Illinois, was that it would disappear in approximately three years, returning the blood vessel to a near-native state.

A disappearing stent, if you will. Abbott launched Absorb in India in Dec 2012, more than three years before the US approved it for sale.

Meril’s management wanted to produce its own version, but cheaper than Abbott’s Rs 1.95 lakh-device ($2,684). By 2017, they had developed “MeRes100”. Indian regulators soon approved it for sale. Meril claims it invested between Rs 150 and 200 crore ($21 to 27.5 million). It saw a big market—tens of millions of Indians die from cardiovascular disease every year and more than half a million people get stents. Even if Meril supplied a fraction of those people with its high-end device, it would laugh all the way to the bank.  

But MeRes100 never launched in India.

Instead, the device got caught in a perfect storm of bad publicity and regulation. Rumours about Abbott’s Absorb having some risk of heart attack, thrombosis (blood clot) and death in patients surfaced, tainting MeRes100 by extension. In Sept 2017, Abbott pulled Absorb from the market. More than 500 injuries and deaths related to the device have been reported to US regulators. “There is a kind of atmosphere that’s been created because of Absorb that [MeRes100] will not work,” said Gautam Tripathy, national sales head at Meril. At the same time, Indian regulators capped stent prices at Rs 29,600, eating into Meril’s potential profits.

Meril claims it has succeeded where Abbott failed. That’d be remarkable; Meril’s revenue last year was $40 million (Rs 288 crore), 1/700th of Abbott’s $28 billion (Rs 2 lakh crore). And the company has yet to prove that MeRes100 is any better than existing stents, experts say. In the wake of Abbott’s failure, Meril needs to up its scrutiny and follow hundreds of patients for multiple years before saying with confidence that its device is better than existing stents. That’d be the standard for approval in the US. And that’d cost hundreds of crores of rupees, money that few Indian device manufacturers have in their R&D budgets.

In fact, the economics of clinical trials makes such little sense for Indian companies that it was only the past weekend—more than 22 years after the development of the first Indian stent—that a domestic stent maker, Sahajanand Medical Technologies, completed a clinical trial that’s truly comparable to ones by multinationals like Abbott. 


Gayathri Vaidyanathan

Gayathri writes on health, environment and science. She has reported and produced stories for the Washington Post, Discover, Nature, and the New York Times, amongst other publications. In her last assignment, she was the lead science writer for E&E News in Washington, D.C. E&E News is a news organisation focused on energy and the environment. Over the past decade, Gayathri has travelled across North America, Africa and Asia on long-form reporting projects. She has a master’s in journalism from Columbia University and a bachelor's in biochemistry from McMaster University in Ontario. At The Ken, Gayathri will write on healthcare, the pharmaceutical business and the environment. Based in Bengaluru, you can reach her at gayathri at the rate

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?


Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750


Quarterly Subscription

3-month access to 60+ new stories with 3-months worth of archives from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 1,750


Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500


Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120


Quarterly Subscription

3-month access to 35+ stories from Southeast Asia.

$ 50


Single Story

Instant access to this story for a year along with comment privileges.

$ 20



What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at detailing the error or queries.